KR101660360B1 - Ｃ형 간염 치료용 우라실 또는 티민 유도체 - Google Patents

Ｃ형 간염 치료용 우라실 또는 티민 유도체 Download PDF

Info

Publication number
KR101660360B1
KR101660360B1 KR1020157010052A KR20157010052A KR101660360B1 KR 101660360 B1 KR101660360 B1 KR 101660360B1 KR 1020157010052 A KR1020157010052 A KR 1020157010052A KR 20157010052 A KR20157010052 A KR 20157010052A KR 101660360 B1 KR101660360 B1 KR 101660360B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
independently selected
optionally substituted
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157010052A
Other languages
English (en)
Korean (ko)
Other versions
KR20150117632A (ko
Inventor
롤프 와그너
마이클 디. 투파노
켄트 디. 스튜어트
토드 더블유. 록웨이
존 티. 랜돌프
존 케이. 프라트
크리스토퍼 이. 모터
클라런스 제이. 마링
켄튼 엘. 롱게네커
야야 류
다춘 류
알랜 씨. 크루거
워렌 엠. 카티
더글라스 케이. 허친슨
페기 피. 황
찰스 에이. 플렌지
파멜라 엘. 도너
데이비드 에이. 데고이
데이비드 에이. 베테베너
데이비드 엠. 반즈
솽 천
2세 테디어스 에스. 프란크직
이 가오
안토니 알. 헤이트
존 이. 헨지벨드
로저 에프. 헨리
브라이언 제이. 코테키
샤오춘 러우
캐시 사리스
제프 지. 제트. 장
Original Assignee
애브비 바하마스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101660360(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애브비 바하마스 리미티드 filed Critical 애브비 바하마스 리미티드
Publication of KR20150117632A publication Critical patent/KR20150117632A/ko
Application granted granted Critical
Publication of KR101660360B1 publication Critical patent/KR101660360B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020157010052A 2007-09-17 2008-09-17 Ｃ형 간염 치료용 우라실 또는 티민 유도체 Expired - Fee Related KR101660360B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US60/972,877 2007-09-17
US9679108P 2008-09-13 2008-09-13
US61/096,791 2008-09-13
PCT/US2008/076576 WO2009039127A1 (en) 2007-09-17 2008-09-17 Uracil or thymine derivative for treating hepatitis c

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008431A Division KR101552474B1 (ko) 2007-09-17 2008-09-17 Ｃ형 간염 치료용 우라실 또는 티민 유도체

Publications (2)

Publication Number Publication Date
KR20150117632A KR20150117632A (ko) 2015-10-20
KR101660360B1 true KR101660360B1 (ko) 2016-09-27

Family

ID=39948002

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157010052A Expired - Fee Related KR101660360B1 (ko) 2007-09-17 2008-09-17 Ｃ형 간염 치료용 우라실 또는 티민 유도체
KR1020107008431A Active KR101552474B1 (ko) 2007-09-17 2008-09-17 Ｃ형 간염 치료용 우라실 또는 티민 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107008431A Active KR101552474B1 (ko) 2007-09-17 2008-09-17 Ｃ형 간염 치료용 우라실 또는 티민 유도체

Country Status (30)

Country Link
US (3) US8415351B2 (OSRAM)
EP (2) EP2725015A1 (OSRAM)
JP (2) JP5734654B2 (OSRAM)
KR (2) KR101660360B1 (OSRAM)
CN (2) CN102746239B (OSRAM)
AR (2) AR070027A1 (OSRAM)
AU (1) AU2008302448B2 (OSRAM)
BR (1) BRPI0816994B8 (OSRAM)
CA (2) CA2699981C (OSRAM)
CL (2) CL2008002794A1 (OSRAM)
CO (1) CO6260076A2 (OSRAM)
CR (2) CR11316A (OSRAM)
DO (2) DOP2010000084A (OSRAM)
ES (1) ES2453591T3 (OSRAM)
GT (1) GT201000061A (OSRAM)
IL (1) IL204547A (OSRAM)
IN (1) IN2012DN05113A (OSRAM)
MX (2) MX2010002905A (OSRAM)
MY (1) MY162760A (OSRAM)
NZ (3) NZ618277A (OSRAM)
PA (1) PA8796201A1 (OSRAM)
PE (2) PE20090705A1 (OSRAM)
PH (1) PH12013500365A1 (OSRAM)
RU (2) RU2543620C2 (OSRAM)
SG (1) SG183733A1 (OSRAM)
TW (2) TWI437994B (OSRAM)
UA (1) UA117800C2 (OSRAM)
UY (1) UY31344A1 (OSRAM)
WO (1) WO2009039127A1 (OSRAM)
ZA (2) ZA201204223B (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039135A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
WO2009039134A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
IN2012DN05113A (OSRAM) 2007-09-17 2015-10-23 Abbott Lab
CN102099351A (zh) * 2007-11-16 2011-06-15 先灵公司 3-杂环取代的吲哚衍生物及其使用方法
MX2011000656A (es) 2008-07-23 2011-02-23 Hoffmann La Roche Compuestos heterociclicos antiviricos.
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
CA2753825C (en) * 2009-03-24 2017-10-17 Abbott Laboratories Process for preparing substituted pyrimidine antiviral compound
CN102448952B (zh) * 2009-03-25 2014-10-29 Abbvie公司 抗病毒化合物和其用途
JP2012522013A (ja) * 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
AU2010240888A1 (en) 2009-04-25 2011-11-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
AU2010264802A1 (en) * 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
KR20120059626A (ko) 2009-09-21 2012-06-08 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
BR112012012085A2 (pt) * 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
CA2780526A1 (en) * 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
WO2012004212A1 (en) 2010-07-07 2012-01-12 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
CR20180412A (es) * 2010-07-16 2018-11-01 Abbvie Ireland Unlimited Co Proceso para preparar compuestos antivirales
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
CA2806547A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
WO2012129099A1 (en) 2011-03-18 2012-09-27 Abbott Laboratories Formulations of phenyl uracil compounds
CA2830324A1 (en) * 2011-03-31 2012-10-04 Konstanze Schafer Perfluorinated compounds for non-viral transfer of nucleic acids
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
US9040516B2 (en) 2011-08-01 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Uracil derivative and use thereof for medical purposes
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2670667T3 (es) 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
AU2013261130A1 (en) 2012-05-15 2014-10-23 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
MX357305B (es) 2012-05-15 2018-07-04 Novartis Ag Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
NZ701626A (en) 2012-05-15 2016-02-26 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2866807A2 (en) 2012-06-27 2015-05-06 Abbvie Inc. Methods for treating hcv
CN104884440A (zh) * 2012-08-21 2015-09-02 艾伯维公司 用于制备抗病毒化合物的方法
SG11201503051QA (en) 2012-10-18 2015-05-28 Abbvie Inc Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
US20150011481A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
AR096816A1 (es) 2013-07-08 2016-02-03 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con c-n como agentes para combatir parásitos
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
UA121309C2 (uk) 2014-02-03 2020-05-12 Вітае Фармасьютікалс, Ллс Дигідропіролопіридинові інгібітори ror-гамма
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN106573915B (zh) 2014-08-01 2020-12-25 纽韦卢森公司 针对布罗莫结构域有活性的化合物
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
CN108137514A (zh) * 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
MX385332B (es) 2015-11-20 2025-03-18 Vitae Pharmaceuticals Llc Moduladores de ror-gamma.
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN111225914B (zh) 2017-07-24 2022-10-11 生命医药有限责任公司 RORγ的抑制剂
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
WO2021053495A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101552474B1 (ko) * 2007-09-17 2015-09-11 애브비 바하마스 리미티드 Ｃ형 간염 치료용 우라실 또는 티민 유도체

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (OSRAM) 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
JP3824935B2 (ja) * 1999-12-06 2006-09-20 エフ．ホフマン−ラ ロシュ アーゲー ４−ピリミジニル−ｎ−アシル−ｌ−フェニルアラニン
IL167957A (en) 2000-02-04 2009-07-20 Sumitomo Chemical Co Hydroxypyridine compounds
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
WO2009039135A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
MX2011000656A (es) 2008-07-23 2011-02-23 Hoffmann La Roche Compuestos heterociclicos antiviricos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101552474B1 (ko) * 2007-09-17 2015-09-11 애브비 바하마스 리미티드 Ｃ형 간염 치료용 우라실 또는 티민 유도체

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemistry of Heterocyclic Compounds, 18(9), 967-971쪽(1982.)*
The Journal of Organic Chemistry, 71(24), 9183-9190쪽(2006.11.24.)*

Also Published As

Publication number Publication date
AU2008302448B2 (en) 2014-11-06
RU2013104270A (ru) 2014-08-10
CA2699981C (en) 2017-08-22
UA117800C2 (uk) 2018-10-10
GT201000061A (es) 2012-03-26
JP5734654B2 (ja) 2015-06-17
CR11316A (es) 2010-10-05
RU2010114828A (ru) 2011-10-27
NZ584720A (en) 2012-07-27
PH12013500365A1 (en) 2014-09-08
KR20150117632A (ko) 2015-10-20
DOP2010000084A (es) 2010-06-15
EP2222646B1 (en) 2014-01-22
EP2725015A1 (en) 2014-04-30
DOP2010000396A (es) 2013-12-31
US8415351B2 (en) 2013-04-09
MX2010002905A (es) 2010-07-05
KR20100068289A (ko) 2010-06-22
MX338555B (es) 2016-04-20
US9095590B2 (en) 2015-08-04
RU2543620C2 (ru) 2015-03-10
PA8796201A1 (es) 2009-04-23
PE20090705A1 (es) 2009-07-17
RU2599635C2 (ru) 2016-10-10
CA2699981A1 (en) 2009-03-26
US20140235638A1 (en) 2014-08-21
NZ600371A (en) 2014-07-25
ES2453591T3 (es) 2014-04-08
TW201443027A (zh) 2014-11-16
IL204547A0 (en) 2010-11-30
UY31344A1 (es) 2009-04-30
CN101801935B (zh) 2014-12-03
CN102746239A (zh) 2012-10-24
TWI534137B (zh) 2016-05-21
IN2012DN05113A (OSRAM) 2015-10-23
US20110070193A1 (en) 2011-03-24
CN102746239B (zh) 2016-02-10
US8685991B2 (en) 2014-04-01
TW200918066A (en) 2009-05-01
CL2008002794A1 (es) 2009-09-04
HK1147256A1 (en) 2011-08-05
SG183733A1 (en) 2012-09-27
EP2222646A1 (en) 2010-09-01
NZ618277A (en) 2015-07-31
CR20150238A (es) 2015-07-01
MY162760A (en) 2017-07-14
CO6260076A2 (es) 2011-03-22
BRPI0816994B1 (pt) 2019-12-24
JP2013049681A (ja) 2013-03-14
BRPI0816994A2 (pt) 2015-03-24
US20120213733A1 (en) 2012-08-23
CL2013000372A1 (es) 2013-10-04
CA2976793A1 (en) 2009-03-26
ZA201204224B (en) 2015-12-23
ZA201204223B (en) 2015-12-23
BRPI0816994B8 (pt) 2021-05-25
TWI437994B (zh) 2014-05-21
CN101801935A (zh) 2010-08-11
AU2008302448A1 (en) 2009-03-26
WO2009039127A1 (en) 2009-03-26
AR070027A1 (es) 2010-03-10
KR101552474B1 (ko) 2015-09-11
IL204547A (en) 2016-04-21
JP2010539186A (ja) 2010-12-16
AR087472A2 (es) 2014-03-26
PE20130209A1 (es) 2013-03-24

Similar Documents

Publication Publication Date Title
KR101660360B1 (ko) Ｃ형 간염 치료용 우라실 또는 티민 유도체
CA2699986C (en) Anti-infective pyrimidines and uses thereof
AU2014280939B2 (en) Uracil or thymine derivative for treating hepatitis C
HK1189590A (en) Anti-infective pyrimidines and uses thereof
HK1189590B (en) Anti-infective pyrimidines and uses thereof
HK1156033B (en) Anti-infective pyrimidines and uses thereof
HK1148273B (en) Anti-infective pyrimidines and uses thereof
AU2013202002A1 (en) Uracil or thymine derivative for treating hepatitis C
HK1177457B (en) Anti-infective pyrimidines and uses thereof
HK1177457A (en) Anti-infective pyrimidines and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 2, Claim Number : 1, 2, Period Limitation Text : 169, Comment Text : 28

St.27 status event code: A-4-4-G10-G18-tex-PA0101

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 2, Claim Number : 1, 2, Period Limitation Text : 169, Comment Text : 28

St.27 status event code: A-4-4-G10-G20-tex-PE0702

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20200922

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200922

St.27 status event code: N-4-6-H10-H13-oth-PC1903